tradingkey.logo

Veracyte Inc

VCYT

23.960USD

+0.320+1.35%
Horário de mercado ETCotações atrasadas em 15 min
1.88BValor de mercado
56.77P/L TTM

Veracyte Inc

23.960

+0.320+1.35%
Mais detalhes de Veracyte Inc Empresa
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.
Informações da empresa
Código da empresaVCYT
Nome da EmpresaVeracyte Inc
Data de listagemOct 30, 2013
CEOMr. Marc A. Stapley
Número de funcionários824
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 30
Endereço6000 Shoreline Court, Suite 300
CidadeSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal94080
Telefone16502436300
Sitehttps://www.veracyte.com/
Código da empresaVCYT
Data de listagemOct 30, 2013
CEOMr. Marc A. Stapley
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Chief Executive Officer, Director
Chief Executive Officer, Director
116.51K
-7.46%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
62.45K
+17.55%
Ms. Rebecca Chambers
Ms. Rebecca Chambers
Chief Financial Officer
Chief Financial Officer
33.34K
-13.87%
Dr. Eliav Barr, M.D.
Dr. Eliav Barr, M.D.
Independent Director
Independent Director
32.81K
+39.68%
Mr. Evan Jones
Mr. Evan Jones
Independent Director
Independent Director
32.19K
+40.76%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
27.84K
+20.48%
Mr. Jens Holstein
Mr. Jens Holstein
Independent Director
Independent Director
25.73K
+56.82%
Dr. Phillip G. (Phil) Febbo, M.D.
Dr. Phillip G. (Phil) Febbo, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
13.09K
-18.41%
Ms. Karin Eastham, CPA
Ms. Karin Eastham, CPA
Independent Director
Independent Director
11.76K
+67.35%
Ms. Annie Mcguire
Ms. Annie Mcguire
Chief Human Resources Officer, General Counsel
Chief Human Resources Officer, General Counsel
10.19K
-25.60%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Chief Executive Officer, Director
Chief Executive Officer, Director
116.51K
-7.46%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
62.45K
+17.55%
Ms. Rebecca Chambers
Ms. Rebecca Chambers
Chief Financial Officer
Chief Financial Officer
33.34K
-13.87%
Dr. Eliav Barr, M.D.
Dr. Eliav Barr, M.D.
Independent Director
Independent Director
32.81K
+39.68%
Mr. Evan Jones
Mr. Evan Jones
Independent Director
Independent Director
32.19K
+40.76%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
27.84K
+20.48%
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2024
FY2023
FY2022
FY2021
FY2020
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
423.54M
95.01%
International
22.23M
4.99%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
10.53%
BlackRock Institutional Trust Company, N.A.
7.92%
Fidelity Management & Research Company LLC
7.88%
Artisan Partners Limited Partnership
6.69%
Wellington Management Company, LLP
4.92%
Other
62.06%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
10.53%
BlackRock Institutional Trust Company, N.A.
7.92%
Fidelity Management & Research Company LLC
7.88%
Artisan Partners Limited Partnership
6.69%
Wellington Management Company, LLP
4.92%
Other
62.06%
Tipos de investidores
Investidores
Proporção
Investment Advisor
59.74%
Investment Advisor/Hedge Fund
38.69%
Hedge Fund
4.35%
Research Firm
1.79%
Pension Fund
1.28%
Venture Capital
0.97%
Individual Investor
0.59%
Bank and Trust
0.44%
Sovereign Wealth Fund
0.29%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
597
84.71M
108.17%
-889.52K
2025Q1
612
85.86M
109.67%
-679.43K
2024Q4
593
81.64M
104.75%
-2.62M
2024Q3
567
81.88M
106.62%
-2.30M
2024Q2
533
81.65M
106.83%
-3.86M
2024Q1
532
81.30M
103.75%
+1.22M
2023Q4
524
76.49M
104.40%
-3.87M
2023Q3
520
77.05M
105.90%
-3.78M
2023Q2
516
77.28M
106.70%
-4.52M
2023Q1
533
77.62M
107.25%
-6.79M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
8.25M
10.53%
+52.03K
+0.64%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.21M
7.92%
-41.84K
-0.67%
Mar 31, 2025
Fidelity Management & Research Company LLC
6.17M
7.88%
+4.15M
+205.06%
Mar 31, 2025
Artisan Partners Limited Partnership
5.24M
6.69%
-1.36M
-20.60%
Mar 31, 2025
Wellington Management Company, LLP
3.85M
4.92%
-231.44K
-5.67%
Mar 31, 2025
ARK Investment Management LLC
3.21M
4.09%
-286.15K
-8.20%
May 31, 2025
ArrowMark Colorado Holdings, LLC
3.23M
4.12%
+146.65K
+4.76%
Mar 31, 2025
State Street Global Advisors (US)
3.16M
4.03%
+247.55K
+8.50%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
2.91M
3.72%
+28.17K
+0.98%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.93M
2.47%
+94.91K
+5.16%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
ARK Genomic Revolution ETF
3.09%
First Trust NYSE Arca Biotechnology Index Fund
2.67%
Global X Genomics & Biotechnology ETF
2.67%
Invesco Biotechnology & Genome ETF
2.57%
WisdomTree BioRevolution Fund
1.69%
ROBO Global Healthcare Technology & Innovation ETF
1.42%
ROBO Global Artificial Intelligence ETF
1.24%
ARK Innovation ETF
0.98%
Franklin Genomic Advancements ETF
0.88%
SPDR S&P Biotech ETF
0.74%
Ver Mais
ARK Genomic Revolution ETF
Proporção3.09%
First Trust NYSE Arca Biotechnology Index Fund
Proporção2.67%
Global X Genomics & Biotechnology ETF
Proporção2.67%
Invesco Biotechnology & Genome ETF
Proporção2.57%
WisdomTree BioRevolution Fund
Proporção1.69%
ROBO Global Healthcare Technology & Innovation ETF
Proporção1.42%
ROBO Global Artificial Intelligence ETF
Proporção1.24%
ARK Innovation ETF
Proporção0.98%
Franklin Genomic Advancements ETF
Proporção0.88%
SPDR S&P Biotech ETF
Proporção0.74%
Dividendo
Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
KeyAI